MECHANISM OF ACTION OF THE LUPUS ANTICOAGULANT
S. Shapiro,P. Thiagarajan,L. Marco
DOI: https://doi.org/10.1111/j.1749-6632.1981.tb29748.x
IF: 6.499
1981-06-01
Annals of the New York Academy of Sciences
Abstract:The coagulation inhibitor known as the “lupus anticoagulant” was first clearly described in systemic lupus erythematosus (SLE) by Conley and Hartmann in 1952.l Since then, numerous inhibitors of this type have been described in SLE and in other conditions.* The phenomenon is characterized by prolongation of lipid-dependent coagulation tests, especially the prothrombin time, partial thromboplastin time and Russell’s viper venom time, and by variable deficits of one or more coagulation factors, often factors VIII, IX, or XI. In addition, occasional patients with SLE and a lupus anticoagulant have isolated deficits of pr~thrombin.~ Although most evidence has pointed to the immunoglobulin nature of these inhibitors, their precise mechanism of action has been difficult to elucidate. Despite the coagulation abnormalities, patients with lupus anticoagulants rarely bleed. This apparent dissociation of laboratory and clinical findings suggested that an understandipg of lupus anticoagulants might contribute some insights into the physiology of the hemostatic mechanism. We have studied a patient with Waldenstrom’s macroglobulinemia whose IgMA paraprotein was a lupus anti~oagulant.~ We were able to demonstrate that this paraprotein had immunologic specificity towards phospholipids with a net negative charge. By virtue of this specificity, the paraprotein interfered with the ability of the vitamin K-dependent, y-carboxyglutamic acid (gla) containing, coagulation factors to bind to phospholipid micelles in the presence of calcium ions, accounting for the abnormalities in coagulation tests. We have examined several lupus inhibitors in patients with SLE and have found that these, too, are immunoglobulins possessing specificity towards anionic phospholipids. The screening studies in our macroglobulinemic patient are shown in TABLE 1. Prothrombin time, partial thromboplastin time, Russell’s viper venom time, and Taipan snake venom time, all tests depending upon the presence of phospholipid, are prolonged. In addition, one-stage assays for factors V, VIII, IX, X, and XI, all of which utilize phospholipid, were moderately to severely depressed. In contrast, the Echis carinatus time of patient plasma was normal; Echis carinatus venom contains an enzyme capable of activating prothrombin directly, without need for phospholipid. Prolongations in these tests were independent of the source of tissue factor or phospholipid, When the patient’s IgMX paraprotein was purified and added to normal plasma, inhibition of all the same tests began to be noted at paraprotein concentrations of 20 mg/dl. This effect is illustrated for the Russell’s viper venom time in FIGURE 1. For comparison, concentration of the paraprotein in the patient’s own plasma was 2-3 gm/dl. In order to demonstrate the immunologic nature